<Lecture>

The present invention relates to five novel substances contained in spinach. This is for the prevention and treatment of respiratory(pneumonia/asthma/chronic obstructive pulmonary disease) and male/female menopause.

Specifically, anti-inflammatory effects on acute/chronic pulmonary inflammation were confirmed on spinach extract extracted with 30% alcohol through three animal models.

A 26-week-old white mouse was used as an experimental model for improving men's menopause and muscle loss, and animal mice were orally administered for 4 weeks to evaluate their effectiveness on reducing androgen symptoms.

In addition, as an experimental model for women's menopausal osteoporosis syndrome, we used rats fed calcium-deficient, ovariectomized, and evaluated the improvement effect of complex SOAH on menopausal syndrome (osteoporosis, lipid metabolism abnormalities, etc.).​ 

<Speaker>

The research interests of Dr. Ryu are on the isolation, characterization and biological evaluation of natural products of higher plant origin, and he has worked in particular on compounds with potential chronic inflammatory diseases and metabolic diseases, in addition to the scientific study of botanical dietary supplements. 

<Lecture>

Switzerland is home to a unique global life sciences cluster, serving as the center of a deep network of startups and SMEs alongside international companies such as Novartis and Roche. Its world-class universities, strong intellectual property protection system, and strategic geographical location at the heart of Europe have made Switzerland a preferred destination for global and neighboring pharmaceutical companies. Switzerland offers a dynamic talent pool and a robust ecosystem that provides significant advantages to companies. This ecosystem allows access to the entire value chain from R&D to product manufacturing in one place. For many companies looking to rapidly and easily integrate new innovations in personalized medicine, Switzerland offers the optimal environment. Additionally, its practical and business-friendly legal system attracts companies that develop fast-growing, high-quality "Swiss" products. This lecture will provide extensive information on Switzerland's pharmaceutical and biotechnology industries and introduce business opportunities in Switzerland. 

<Speaker>

Okjeong Baik, Deputy Head of the Swiss Business Hub Korea at the Embassy of Switzerland, is an expert in consulting for overseas companies entering the Korean market and for Korean companies' overseas direct investments. Since the opening of the Swiss Business Hub Korea in October 2010, she has been providing consulting services for Swiss SMEs' exports to Korea and Korean companies' direct investments in Switzerland. She has also served as a Senior Commercial Officer in the Economic and Trade Office of the Embassy of Israel and worked at Dow Corning Korea in Seoul, Korea. She graduated from Ewha Woman’s University with a degree in law and is currently pursuing a PhD in Business Administration at the Graduate School of Business of Ewha Woman’s University (ABD). 

<Lecture>

Most rare diseases are caused by genetic factors, and providing diagnostic information through genomic analysis is a process of finding vast amounts of data on the relationship between genetic variation and disease, which requires AI. Finding genetic variation based on AI and providing quick and accurate suggestions for diseases and their treatments is expected to save lives, especially of newborns who need medical intervention as early as possible. At the same time, it is also expected to help achieve sustainable healthcare by reducing the time and burden on clinicians, resolving manpower shortages and social conflicts, and expanding access to medical care for newborns with rare diseases who face significant unmet medical needs. 

<Speaker>

Taehyuk Kwon is the Chief Operating Officer of MedySapiens, a company specializing in AI-based genomic analysis. He majored in statistics and technology strategy/policy and has been conducting research and business planning on technology companies, such as influencing factors on corporate growth and sustainability, and planning for government-supported projects. Currently, he is in charge of the business of MedySapiens, including B2G strategy, technology sales, and investment, based on his long experience in the public sector and understanding of the government procurement market 

<Lecture>

Rznomics’ core technology, the trans-splicing ribozyme-based RNA editing Therapeutics, is a technology in which the trans-splicing ribozyme specifically targets and cleaves disease-causing RNA, and replaces with therapeutic RNA to induce the therapeutic effect. This leads to the suppression of the expression of the target RNA and simultaneous induction of therapeutic gene expression with high specificity and efficacy. Moreover, the technology allows the regulation of therapeutic gene expression and targeting and editing of variable mutation sites with one molecule, and therefore it has a great potential to be applied as gene therapies for various human intractable diseases. 

<Speaker>

Seong-Wook Lee is the CEO and President of Rznomics Inc. who has established the company in 2017. He has over 30 years of academic and industry experience and has extensive knowledge about Gene Therapy. With expertise in the field, he is in charge of the overall R&D, clinical development and management of the company. His leadership led to remarkable achievements such as obtaining IND approval from the US FDA and Korea MFDS, receiving Orphan Drug Designation (ODD) and Fast track designation from the US FDA, being selected for DIPS 1000+ project by the Ministry of SMEs and Startups, and being selected as the first and the only company for National Strategic Technology Confirmation System by Ministry of Science and ICT. 

 <Lecture>

Organoids, created through 3D culture technology to model miniature human tissues, are gaining significant attention in the life sciences. This revolutionary technology is utilized in disease research, drug testing, and personalized medicine, emerging as an alternative to organ transplantation. Organoids can model various organs, including the nervous system, digestive system, and liver, greatly enhancing research efficiency. In the future, more sophisticated organoid development is expected to shorten drug development timelines and advance personalized treatments. Organoids present a new paradigm in life sciences, contributing to the improvement of human health. 

<Speaker>

Kyung Jin Lee is the Chief Technology Officer and co-founder at ORGANOIDSCIENCES LTD, one of leading biotech company to develop innovated organoid technology. Kyung Jin Lee has over 10 years of academic and biotechnology experience with expertise in biochemistry and biology. 

Throughout his experience, he is in charge developing organoid technology especially in regulatory requirements concerning development, manufacturing, CMC, quality, non-clinical aspects for organoid-based regenerative medicine​